The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Bactericidal versus bacteriostatic antibacterials: clinical significance, differences and synergistic potential in clinical practice
Abstract
Antibacterial activity can be classified as either bactericidal or bacteriostatic, using methods such as the MBC/MIC ratio and time–kill curves. However, such categorization has proven challenging in clinical practice, as these definitions only apply under specific laboratory conditions, which may differ from clinical settings. Several factors, such as the specific bacteria or infectious medium, can affect the action of antibiotics, with many antibacterials exerting both activities. These definitions have also led to the belief that bactericidal antibacterials are superior to bacteriostatic, especially in more severe cases, such as endocarditis, neutropenia and bacteraemia. Additionally, current dogma dictates against the combination of bactericidal and bacteriostatic antibacterials in clinical practice, due to potential antagonism. This review aimed to assess the differences in antibacterial activity of bactericidal and bacteriostatic antibacterials based on in vitro and in vivo studies and examine their antagonistic or synergistic effects. Our findings show that specific bacteriostatic agents, such as linezolid and tigecycline, are clinically non-inferior to bactericidals in multiple infections, including pneumonia, intra-abdominal infections, and skin and soft tissue infections. Studies also support using several bacteriostatic agents as salvage therapies in severe infections, such as neutropenic fever and endocarditis. Additionally, not all combinations of bacteriostatic and bactericidal agents appear to be antagonistic, with many combinations, such as linezolid and rifampicin, already being used. The findings should be interpreted with caution, as most evidence is from observational studies and there is a need for randomized controlled trials to assess their effectiveness and combinations, especially within the context of rising antimicrobial resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“using MBC/MIC ratios and a threshold of ≦4 to indicate bactericidal activity (Ishak et al. 2025)”
From Linking chemical-composition to antimicrobial efficacy: development of an essential oil-based topical gel prototype (2025) · cites this paper as Ishak et al. 2025
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
The eagle effect and antibiotic-induced persistence: two sides of the same coin?
Prasetyoputri, A., Jarrad, A. M., Cooper, M. A., & Blaskovich, M. A. T. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2018.10.007 · Cited by 101
Linezolid therapy for infective endocarditis
Muñoz, P., Rodríguez-Creixéms, M., Moreno, M., Marín, M., Ramallo, V., Bouza, E., & GAME Study Group (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01585.x · Cited by 68
Research works printed but not linked: 113
- Pankey, 2004, Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections, Clin Infect Dis, 38, 864, 10.1086/381972 · DOI · Paper page
- Wald-Dickler, 2018, Busting the myth of ‘static vs cidal’: a systemic literature review, Clin Infect Dis, 66, 1470, 10.1093/cid/cix1127 · DOI · Paper page
- Mogana, 2020, Antibacterial activities of the extracts, fractions and isolated compounds from Canarium patentinervium Miq. against bacterial clinical isolates, BMC Complement Med Ther, 20, 55, 10.1186/s12906-020-2837-5 · DOI · Paper page
- Levison, 2009, Pharmacokinetics and pharmacodynamics of antibacterial agents, Infect Dis Clin North Am, 23, 791, 10.1016/j.idc.2009.06.008 · DOI · Paper page
- Baquero, 2021, Proximate and ultimate causes of the bactericidal action of antibiotics, Nat Rev Microbiol, 19, 123, 10.1038/s41579-020-00443-1 · DOI · Paper page
- Craig, 1993, Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens, Eur J Clin Microbiol Infect Dis, 12, S6, 10.1007/BF02389870 · doi:10.1007/bf02389870
- Ambrose, 2007, Antimicrobial resistance: pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore, Clin Infect Dis, 44, 79, 10.1086/510079 · DOI · Paper page
- Steigbigel, 2019, Static vs cidal antibiotics, Clin Infect Dis, 68, 351, 10.1093/cid/ciy645 · DOI
- Zahedi Bialvaei, 2017, Linezolid: a promising option in the treatment of gram-positives, J Antimicrob Chemother, 72, 354, 10.1093/jac/dkw450 · DOI · Paper page
- Watkins, 2012, An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy, Core Evid, 7, 131, 10.2147/CE.S33430 · DOI
- Clemett, 2000, Linezolid, Drugs, 59, 815, 10.2165/00003495-200059040-00007 · doi:10.2165/00003495-200059040-00007
- Scott, 2019, Eravacycline: a review in complicated intra-abdominal infections, Drugs, 79, 315, 10.1007/s40265-019-01067-3 · DOI
- Silva, 2011, Bacteriostatic versus bactericidal activity of ciprofloxacin in Escherichia coli assessed by flow cytometry using a novel far-red dye, J Antibiot, 64, 321, 10.1038/ja.2011.5 · DOI
- Rahal, 1979, Bactericidal and bacteriostatic action of chloramphenicol against meningeal pathogens, Antimicrob Agents Chemother, 16, 13, 10.1128/AAC.16.1.13 · doi:10.1128/aac.16.1.13
- Stein, 2006, Tigecycline: a critical analysis, Clin Infect Dis, 43, 518, 10.1086/505494 · DOI · Paper page
- Greer, 2006, Tigecycline (tygacil): the first in the glycylcycline class of antibiotics, Baylor Univ Med Cent), 19, 155, 10.1080/08998280.2006.11928154 · doi:10.1080/08998280.2006.11928154
- Johansen, 2000, Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo, J Antimicrob Chemother, 46, 973, 10.1093/jac/46.6.973 · DOI
- Daschner, 1976, Combination of bacteriostatic and bactericidal drugs: lack of significant in vitro antagonism between penicillin, cephalothin, and rolitetracycline, Antimicrob Agents Chemother, 10, 802, 10.1128/AAC.10.5.802 · DOI
- Weeks, 1981, Antagonism of ampicillin and chloramphenicol for meningeal isolates of group B streptococci, Antimicrob Agents Chemother, 20, 281, 10.1128/AAC.20.3.281 · doi:10.1128/aac.20.3.281
- Singh, 2017, Suppressive drug combinations and their potential to combat antibiotic resistance, J Antibiot, 70, 1033, 10.1038/ja.2017.102 · DOI
- Allison, 1992, Effect of polysaccharide interactions on antibiotic susceptibility of Pseudomonas aeruginosa, J Appl Bacteriol, 73, 484, 10.1111/j.1365-2672.1992.tb05009.x · DOI
- Chevereau, 2015, Systematic discovery of drug interaction mechanisms, Mol Syst Biol, 11, 807, 10.15252/msb.20156098 · DOI
- Ocampo, 2014, Antagonism between bacteriostatic and bactericidal antibiotics is prevalent, Antimicrob Agents Chemother, 58, 4573, 10.1128/AAC.02463-14 · DOI · Paper page
- Iversen, 2019, Partial oral versus intravenous antibiotic treatment of endocarditis, N Engl J Med, 380, 415, 10.1056/NEJMoa1808312 · DOI · Paper page
- Jacqueline, 2003, In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods, J Antimicrob Chemother, 51, 857, 10.1093/jac/dkg160 · DOI
- Valderrama, 2020, Synergy of linezolid with several antimicrobial agents against linezolid-methicillin-resistant staphylococcal strains, Antibiotics, 9, 496, 10.3390/antibiotics9080496 · DOI
- Jiang, 2021, Synergistic combination of linezolid and fosfomycin closing each other’s mutant selection window to prevent enterococcal resistance, Front Microbiol, 11, 605962, 10.3389/fmicb.2020.605962 · DOI
- Leijtens, 2017, Clindamycin-rifampin combination therapy for staphylococcal periprosthetic joint infections: a retrospective observational study, BMC Infect Dis, 17, 321, 10.1186/s12879-017-2429-2 · doi:10.1186/s12879-017-2429-2
- Bonnaire, 2021, Clindamycin combination treatment for the treatment of bone and joint infections caused by clindamycin-susceptible, erythromycin-resistant Staphylococcus spp, Diagn Microbiol Infect Dis, 99, 115225, 10.1016/j.diagmicrobio.2020.115225 · DOI
- Ochi, 2018, The effect of oral clindamycin and rifampicin combination therapy in patients with hidradenitis suppurativa in Singapore, Clin Cosmet Investig Dermatol, 11, 37, 10.2147/CCID.S136730 · doi:10.2147/ccid.s136730
- Albur, 2012, Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae, Antimicrob Agents Chemother, 56, 3441, 10.1128/AAC.05682-11 · DOI
- Zhou, 2020, Colistin combined with tigecycline: a promising alternative strategy to combat Escherichia coli harboring blaNDM-5 and mcr-1, Front Microbiol, 10, 2957, 10.3389/fmicb.2019.02957 · DOI
- Sato, 2021, Effects of colistin and tigecycline on multidrug-resistant Acinetobacter baumannii biofilms: advantages and disadvantages of their combination, Sci Rep, 11, 11700, 10.1038/s41598-021-90732-3 · DOI
- Chusri, 2019, Adjunctive therapy of intravenous colistin to intravenous tigecycline for adult patients with non-bacteremic post-surgical intra-abdominal infection due to carbapenem-resistant Acinetobacter baumannii, J Infect Chemother, 25, 681, 10.1016/j.jiac.2019.03.017 · DOI
- Amat, 2018, The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii, Clin Microbiol Infect, 24, 630, 10.1016/j.cmi.2017.09.016 · DOI
- Hespanhol, 2020, Pneumonia mortality, comorbidities matter?, Pulmonology, 26, 123, 10.1016/j.pulmoe.2019.10.003 · doi:10.1016/j.pulmoe.2019.10.003
- Pletz, 2020, International perspective on the new 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia guideline: a critical appraisal by a global expert panel, Chest, 158, 1912, 10.1016/j.chest.2020.07.089 · DOI
- Bohte, 1995, Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia, Eur J Clin Microbiol Infect Dis, 14, 182, 10.1007/BF02310353 · DOI
- Genné, 1997, Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia, Eur J Clin Microbiol Infect Dis, 16, 783, 10.1007/BF01700406 · doi:10.1007/bf01700406
- Kuzman, 2005, Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study, J Chemother, 17, 636, 10.1179/joc.2005.17.6.636 · DOI
- Dartois, 2008, Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience, J Chemother, 20, 28, 10.1179/joc.2008.20.Supplement-1.28 · DOI
- Tanaseanu, 2008, Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia, Diagn Microbiol Infect Dis, 61, 329, 10.1016/j.diagmicrobio.2008.04.009 · DOI
- Bergallo, 2009, Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin, Diagn Microbiol Infect Dis, 63, 52, 10.1016/j.diagmicrobio.2008.09.001 · DOI
- Mokabberi, 2010, Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia, J Clin Pharm Ther, 35, 195, 10.1111/j.1365-2710.2009.01073.x · DOI
- Stets, 2019, Omadacycline for community-acquired bacterial pneumonia, N Engl J Med, 380, 517, 10.1056/NEJMoa1800201 · DOI · Paper page
- Rodriguez, 2023, Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a post-hoc analysis of the phase 3 OPTIC trial, Front Med (Lausanne), 10, 1225710, 10.3389/fmed.2023.1225710 · doi:10.3389/fmed.2023.1225710
- Ramirez, 2021, Efficacy of omadacycline versus moxifloxacin in the treatment of community-acquired bacterial pneumonia by disease severity: results from the OPTIC study, Open Forum Infect Dis, 8, ofab135, 10.1093/ofid/ofab135 · doi:10.1093/ofid/ofab135
- Kadowaki, 2005, Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients, Chest, 127, 1276, 10.1378/chest.127.4.1276 · doi:10.1378/chest.127.4.1276
- Freire, 2010, Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia, Diagn Microbiol Infect Dis, 68, 140, 10.1016/j.diagmicrobio.2010.05.012 · DOI · Paper page
- Ramirez, 2013, Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia, Antimicrob Agents Chemother, 57, 1756, 10.1128/AAC.01232-12 · DOI · Paper page
- Wang, 2015, Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis, Eur J Clin Pharmacol, 71, 107, 10.1007/s00228-014-1775-x · DOI
- Kato, 2021, Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus, J Glob Antimicrob Resist, 24, 98, 10.1016/j.jgar.2020.12.009 · DOI
- Nemeth, 2015, Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis, J Antimicrob Chemother, 70, 382, 10.1093/jac/dku379 · DOI · Paper page
- Saleem, 2022, Mortality and clinical cure rates for pneumonia: a systematic review, meta-analysis, and trial sequential analysis of randomized control trials comparing bactericidal and bacteriostatic antibiotic treatments, Clin Microbiol Infect, 28, 936, 10.1016/j.cmi.2021.12.021 · DOI
- Eckmann, 2013, Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies, J Antimicrob Chemother, 68, ii25, 10.1093/jac/dkt142 · DOI
- Oliva, 2005, A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections, BMC Infect Dis, 5, 88, 10.1186/1471-2334-5-88 · DOI
- Towfigh, 2010, A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections, Clin Microbiol Infect, 16, 1274, 10.1111/j.1469-0691.2010.03122.x · DOI
- Qvist, 2012, Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial, Surg Infect (Larchmt), 13, 102, 10.1089/sur.2011.048 · DOI
- Alosaimy, 2022, Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii, Microbiol Spectr, 10, e0047922, 10.1128/spectrum.00479-22 · DOI
- Solomkin, 2017, Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) trial: a randomized clinical trial, JAMA Surg, 152, 224, 10.1001/jamasurg.2016.4237 · DOI · Paper page
- Solomkin, 2019, IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections, Clin Infect Dis, 69, 921, 10.1093/cid/ciy1029 · DOI · Paper page
- Meng, 2022, The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: a Bayesian network meta-analysis, Front Med (Lausanne), 9, 935343, 10.3389/fmed.2022.935343 · DOI
- Moffarah, 2016, Skin and soft tissue infections, Microbiol Spectr, 4, 4.4.14, 10.1128/microbiolspec.DMIH2-0014-2015 · DOI
- Eckmann, 2010, Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin, Eur J Med Res, 15, 554, 10.1186/2047-783X-15-12-554 · DOI
- Bartoszko, 2018, Antibiotic therapy for skin and soft tissue infections: a protocol for a systematic review and network meta-analysis, Syst Rev, 7, 138, 10.1186/s13643-018-0804-8 · DOI
- Stevens, 2014, Executive summary: practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America, Clin Infect Dis, 59, 147, 10.1093/cid/ciu444 · DOI · Paper page
- Itani, 2010, Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus, Am J Surg, 199, 804, 10.1016/j.amjsurg.2009.08.045 · DOI
- Wilcox, 2009, Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study, Clin Infect Dis, 48, 203, 10.1086/595686 · DOI · Paper page
- Weigelt, 2005, Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections, Antimicrob Agents Chemother, 49, 2260, 10.1128/AAC.49.6.2260-2266.2005 · DOI · Paper page
- Chuang, 2011, Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan, J Microbiol Immunol Infect, 44, 116, 10.1016/j.jmii.2010.04.002 · DOI
- Sacchidanand, 2005, Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial, Int J Infect Dis, 9, 251, 10.1016/j.ijid.2005.05.003 · DOI
- Cenizal, 2007, Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 51, 2628, 10.1128/AAC.00206-07 · DOI
- Harbarth, 2015, Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection, J Antimicrob Chemother, 70, 264, 10.1093/jac/dku352 · DOI
- Jauregui, 2005, Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections, Clin Infect Dis, 41, 1407, 10.1086/497271 · DOI · Paper page
- Cepeda, 2004, Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study, J Antimicrob Chemother, 53, 345, 10.1093/jac/dkh048 · DOI
- Papadopoulos, 2009, Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: a case-control study, J Chemother, 21, 165, 10.1179/joc.2009.21.2.165 · doi:10.1179/joc.2009.21.2.165
- Zhou, 2023, Comparative study of linezolid and vancomycin regimens in one-stage surgery for treating limb traumatic osteomyelitis caused by methicillin-resistant Staphylococcus aureus, Pol J Microbiol, 72, 239, 10.33073/pjm-2023-024 · DOI
- Sawada, 2019, Linezolid versus daptomycin treatment for periprosthetic joint infections: a retrospective cohort study, J Orthop Surg Res, 14, 334, 10.1186/s13018-019-1375-7 · doi:10.1186/s13018-019-1375-7
- Benavent, 2021, Long-term use of tedizolid in osteoarticular infections: benefits among oxazolidinone drugs, Antibiotics, 10, 53, 10.3390/antibiotics10010053 · doi:10.3390/antibiotics10010053
- Frenck, 2000, Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children, Clin Infect Dis, 31, 1134, 10.1086/317450 · DOI
- Begum, 2014, Comparison between azithromycin and cefixime in the treatment of typhoid fever in children, Mymensingh Med J, 23, 441
- Girgis, 1999, Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance, Antimicrob Agents Chemother, 43, 1441, 10.1128/AAC.43.6.1441 · DOI
- Acharya, 1995, Treatment of typhoid fever: randomized trial of a three-day course of ceftriaxone versus a fourteen-day course of chloramphenicol, Am J Trop Med Hyg, 52, 162, 10.4269/ajtmh.1995.52.162 · DOI
- Arjyal, 2011, Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial, Lancet Infect Dis, 11, 445, 10.1016/S1473-3099(11)70089-5 · DOI
- Marchello, 2020, A systematic review on antimicrobial resistance among salmonella typhi worldwide, Am J Trop Med Hyg, 103, 2518, 10.4269/ajtmh.20-0258 · DOI
- Sebbane, 2021, Antibiotic therapy of plague: a review, Biomolecules, 11, 724, 10.3390/biom11050724 · DOI
- Mwengee, 2006, Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania, Clin Infect Dis, 42, 614, 10.1086/500137 · DOI
- Rafailidis, 2009, Linezolid for patients with neutropenia: are bacteriostatic agents appropriate?, Expert Rev Anti Infect Ther, 7, 415, 10.1586/eri.09.11 · DOI
- Jaksic, 2006, Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer, Clin Infect Dis, 42, 597, 10.1086/500139 · DOI · Paper page
- Bucaneve, 2014, Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia, J Clin Oncol, 32, 1463, 10.1200/JCO.2013.51.6963 · DOI
- Zhou, 2018, Salvage tigecycline in high risk febrile neutropenic patients with hematological malignancies: a prospective multicenter study, Leuk Lymphoma, 59, 2679, 10.1080/10428194.2018.1436173 · doi:10.1080/10428194.2018.1436173
- Modemann, 2022, Efficacy of tigecycline as salvage therapy in multidrug-resistant febrile neutropenia in patients with acute leukemia—a single center analysis, Antibiotics, 11, 128, 10.3390/antibiotics11020128 · doi:10.3390/antibiotics11020128
- Biscarini, 2021, A case of Corynebacterium striatum endocarditis successfully treated with an early switch to oral antimicrobial therapy, Infez Med, 29, 138
- Imoto, 2021, Corynebacterium jeikeium-induced infective endocarditis and perivalvular abscess diagnosed by 16S ribosomal RNA sequence analysis: a case report, J Infect Chemother, 27, 906, 10.1016/j.jiac.2021.01.005 · doi:10.1016/j.jiac.2021.01.005
- Yazaki, 2018, A successful salvage therapy with daptomycin and linezolid for right-sided infective endocarditis and septic pulmonary embolism caused by methicillin-resistant Staphylococcus aureus, J Infect Chemother, 24, 845, 10.1016/j.jiac.2018.02.006 · DOI
- Amiyangoda, 2017, A complicated prosthetic valve endocarditis due to methicillin resistant staphylococci treated with linezolid and ciprofloxacin: a case report, BMC Res Notes, 10, 580, 10.1186/s13104-017-2907-z · DOI
- Hill, 2006, Infective endocarditis treated with linezolid: case report and literature review, Eur J Clin Microbiol Infect Dis, 25, 202, 10.1007/s10096-006-0111-5 · DOI
- Muñoz, 2021, Linezolid for infective endocarditis: a structured approach based on a national database experience, Medicine (Baltimore), 100, e27597, 10.1097/MD.0000000000027597 · DOI
- Lauridsen, 2012, Linezolid as rescue treatment for left-sided infective endocarditis: an observational, retrospective, multicenter study, Eur J Clin Microbiol Infect Dis, 31, 2567, 10.1007/s10096-012-1597-7 · DOI
- Balli, 2014, Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia, Antimicrob Agents Chemother, 58, 734, 10.1128/AAC.01289-13 · DOI · Paper page
- Chuang, 2014, Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis, BMC Infect Dis, 14, 687, 10.1186/s12879-014-0687-9 · DOI
- Seaton, 2015, Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European Cubicin® Outcomes Registry and Experience, Adv Ther, 32, 1192, 10.1007/s12325-015-0267-4 · DOI
- Zhao, 2016, Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysis, Int J Antimicrob Agents, 48, 231, 10.1016/j.ijantimicag.2016.06.010 · DOI
- Shi, 2020, Efficacy and safety of daptomycin versus linezolid treatment in patients with vancomycin-resistant enterococcal bacteraemia: an updated systematic review and meta-analysis, J Glob Antimicrob Resist, 21, 235, 10.1016/j.jgar.2019.10.008 · DOI
- Kawasuji, 2023, Effectiveness and safety of linezolid versus vancomycin, teicoplanin, or daptomycin against methicillin-resistant Staphylococcus aureus bacteremia: a systematic review and meta-analysis, Antibiotics (Basel), 12, 697, 10.3390/antibiotics12040697 · DOI
- Willekens, 2019, Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study, Clin Infect Dis, 69, 381, 10.1093/cid/ciy916 · DOI
- Duke, 2003, Chloramphenicol or ceftriaxone, or both, as treatment for meningitis in developing countries?, Arch Dis Child, 88, 536, 10.1136/adc.88.6.536 · DOI
- Myrianthefs, 2006, Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients, Antimicrob Agents Chemother, 50, 3971, 10.1128/AAC.00051-06 · doi:10.1128/aac.00051-06
- Tsona, 2010, Linezolid penetration into cerebrospinal fluid and brain tissue, J Chemother, 22, 17, 10.1179/joc.2010.22.1.17 · DOI
- Sipahi, 2011, Linezolid in the treatment of methicillin-resistant staphylococcal post-neurosurgical meningitis: a series of 17 cases, Scand J Infect Dis, 43, 757, 10.3109/00365548.2011.585177 · DOI
- Faella, 2006, Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains, Clin Microbiol Infect, 12, 391, 10.1111/j.1469-0691.2006.01352.x · DOI
- Sipahi, 2013, Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus meningitis, Surg Infect (Larchmt), 14, 357, 10.1089/sur.2012.091 · DOI
- Hussain A, 2001, Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review, Scand J Infect Dis, 33, 375, 10.1080/003655401750174048 · doi:10.1080/003655401750174048
Cited by
Aftab, N., Varghese, P., Khalid, A., Umar, A. K., Wallis, C. J., Bates, M., & Hooper, S. E. (2025) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-025-13650-8 · Cited by 2
Metadata
- Authors
- Ishak, A., Mazonakis, N., Spernovasilis, N., Akinosoglou, K., & Tsioutis, C.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-10-29
- Volume
- 80
- Issue
- 1
- Pages
- 1-17
- ISSN
- 0305-7453
- 1460-2091
- Cited by
- 167
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.